Allergy Therapeutics plc (AIM:AGY)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 759.90M |
| Revenue (ttm) | 55.04M |
| Net Income (ttm) | -40.13M |
| Shares Out | 6.33B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,706 |
| Average Volume | 411,372 |
| Open | 11.50 |
| Previous Close | 12.00 |
| Day's Range | 11.00 - 12.00 |
| 52-Week Range | 5.00 - 12.10 |
| Beta | 0.85 |
| RSI | 57.63 |
| Earnings Date | Mar 27, 2026 |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also... [Read more]
Financial Performance
In fiscal year 2025, Allergy Therapeutics's revenue was 55.04 million, a decrease of -0.28% compared to the previous year's 55.20 million. Losses were -40.13 million, 3.91% more than in 2024.
Financial StatementsNews
SMALL CAP IDEA: Allergy Therapeutics transformation has redefined its trajectory
Allergy Therapeutics is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold strategy centred on innovation.
Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%
The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market Size is Expected to Reach USD 42.5 Billion by 2033, according to a rese...
Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”)
Allergy Therapeutics reports a 6% annualised growth in revenue in fiscal 2020
Allergy Therapeutics plc (LON: AGY) said on Wednesday that sales growth in the next financial year was likely to remain flat as COVID-19 restrictions continue to make people avoid visits to the clinic...